UV-Vis spectra were acquired on a Varian Cary 1E UV-Vis system (Varian, Inc., Palo Alto, CA) using PMMA cuvettes.
®
-GV PVDF membrane filter (Millipore Corp.). The initial delay was set to 5 μs, and the final delay to 1 s. Only measurements in which the measured and calculated baselines of the intensity autocorrelation function agreed to within 0.1 % were used to calculate particle size. The calculations of the particle size distributions and distribution averages were performed with the ISDA software package (Brookhaven Instruments Company), which employed single-exponential fitting, cumulants analysis, non-negatively constrained least-squares (NNLS) and CONTIN particle size distribution analysis routines. All determinations were made in quadruplicate.
Materials: SCK 1, 2 and SCK 3, 4 were synthesized as previously reported.
1,2 Doxorubicin was obtained from Sigma-Aldrich (St. Louis, MO.) and was used as received.
General procedure for the preparation of SCK-doxorubicin nanoparticles: A solution of doxorubicin (2.7 mg mL -1 in CH 2 Cl 2 and 3 eq of triethylamine, 30% w/w with respect to the SCK) was added to a vial containing a magnetic stir bar and the SCK solution (4 mL, polymer concentration ~0.25 mg mL -1 ). The solution was protected from light and stirred without cap in a well-ventilated fume hood for 16 h in order evaporate the CH 2 Cl 2 . The solution was then transferred to a centrifugal filter device (Amicon Ultra 4, 30 kDa MWCO, Millipore Corp., Billerica MA, USA) 3 and washed extensively with 5 mM PBS pH 7.4 buffer at 37°C to remove all unincorporated dox. After several washing cycles the filtrate was analyzed by UV-vis (488 nm) to confirm the successful removal of the free dox. The dox-nanoparticle solution was then reconstituted to a final volume of 4 mL. The amount of incorporated DOX was determined by UV-vis (480 nm, ε = 13050 M -1 cm -1 determined by a calibration curve in DMF/PBS 4:1) in a 4:1 v/v mixture of DMF and dox-nanoparticle solution.
General procedure for the release experiments: 2 mL of the dox-nanoparticle solution was transferred to a presoaked dialysis cassette (Slide-A-Lyzer, 10 kDa MWCO, Pierce Biotechnology, Rockford IL, USA). The cassette was then stirred in a beaker containing 4 L of 5 mM PBS at pH 7.4 and 37° C for a period of 48 h. Samples (~100 µL) were removed from the cassette at 0, 1, 2, 3, 4, 8, 16, 24, and 48 h and analyzed by UV-vis (488 nm, ε = 12500 M -1 cm -1 determined by a calibration curve in PBS). All release experiments were conducted in duplicate.
Cell cytotoxicity assay on U87MG-EGFR-v-III cells:
A human glioblastoma cell line that expresses a mutant variant of the EGFR receptor-v-III that was modified to express clickbeetle red luciferase and (Sheila Stewart, unpublished data) and used to test cytotoxicity of dox and dox-SCKs. Briefly, 5000 cells/well were plated in triplicate in 96-well plate 24 h before treatment. Cells were then washed thrice with sterile PBS and exposed to different dose of either free dox or dox-SCKs at 37 °C for 2 h in 10% FBS α MEM. After 2 h of incubation, the cells were washed again thrice with sterile PBS and re-fed with fresh media and further incubated at 37 °C for 70 h before MTT assay. To asses cell viability assay, 10 µL of MTT (5mg ml -1 ) solution was added into each well and incubated at 37 °C for 4 h. The reaction was terminated with 10% SDS stop solution. Absorbance was read at 570 nm using μQuant plate reader (Bio-Tek Instruments, Inc.) and viability was calculated as the percentage of control (cells receiving no treatment).
In vitro fluorescent microscopy study: Cells were prepared as described for the MTT assay above. Cells were treated for 24 h with either 1 µg ml -1 of free-doxorubicin or Dox-loaded NP (SCK 1). Afterwards, cells were fixed with 4% paraformaldehyde at room temperature for 10 min and the nuclei were counterstained with 1 µg ml -1 of DAPI. The fluorescence was observed with an inverted fluorescence microscope (Olympus) with appropriate filter sets.
Apoptosis study of Dox-loaded NPs by flow cytometry: U87MG-EGFRvIII-CBR cells (1x10 6 ) were plated on 12-well plates 24 h before treated with different doses of Dox-loaded NPs and free-dox. After 2 h incubation, cells were washed twice with PBS and re-fed with fresh media containing 10% FBS (fetal bovine serum). At 72 h post treatment, cells were typsinized and washed twice with PBS and then re-suspended into Annexin-V binding buffer. Clearly, the FACS data are consistent with previous MTT results. At higher doses of each SCK sample, there was about 20-30% apoptotic cells, while free dox showed 80% apoptosis at 1000 ng ml -1 . At lower doses (100 ng ml -1 ), the percentages of apoptotic cells were still higher than observed for the untreated control. However, at 10 ng ml -1 , there were no apoptotic effects among all 4 nanoparticles tested; untreated cells also showed some spontaneous apoptosis during the experiment period (72 h).
